Slide 1: Evolving stronger, growing together
Evolving stronger, growing together Analyst presentation 2024 full-year results 5 March 2025
Slide 2: Presenting team
Presenting team Valerie Diele-Braun Hans Kooijmans CEO CFO 2
Slide 3: Highlights 2024, Financials FY2024, Outlook, Q&A, Annex
1 Highlights 2024 2 Financials FY2024 3 Outlook 4 Q&A 5 Annex 3
Slide 4: Highlights 2024: Financial results
Highlights 2024: Financial results Gross profit Operating EBITA Net Result Free cash flow Cash earnings per share EUR 1,202 +3% to million EUR 531 million EUR 278 million EUR 450 million EUR 6.34 +9% on a constant +5% on a constant -4% on a constant 2023: EUR 554 2023: EUR 6.41 currency basis curren
Slide 5: Highlights 2024: M&A
Highlights 2024: M&A Strengthened our presence across all segments • 12 acquisitions completed – adding EUR 300 million in annualised revenues and 493 employees1 • 2 acquisitions signed in 2024 – adding another EUR 33 million revenues and 29 employees1: • Daoqin (China) – Food and nutraceutical ingr
Slide 6: Highlights 2024: acquisitions completed
Highlights 2024: 12 acquisitions completed ● Gova Ingredients (Benelux) – Beauty and personal care (March 2024) EMEA ● Cobapharma (Spain) – Pharmaceutical and nutraceutical industry (July 2024) ● Selechimica (Italy) – Pharmaceutical industry (June 2024) ● Arena (UK) – Pharmaceutical, veterinary and
Slide 7: Continued focus on the six strategic pillars that drive our growth
Continued focus on the six strategic pillars that drive our growth • Launch of SalesAssistant to • 12 acquisitions in 2024 across the • 21 training hrs (2023: 14) empower our people to easily globe to strengthen our presence • 45% women in sub-top identify the right solutions for our across all segm
Slide 8: Financials FY2024
Highlights Financials Outlook Q&A Annex 2024 FY2024
Slide 9: Financials 2024 – income statement
Financials 2024 – income statement fx adj. 2024 2023 change change EUR m change Revenue 4,728 4,443 285 6% 8% Gross profit 1,202 1,123 80 7% 9% Gross profit as a % of revenue 25.4% 25.3% 0.1% Operating EBITDA 572 548 24 4% 6% Operating EBITDA as a % of revenue 12.1% 12.3% (0.2%) Operating EBITA1 531
Slide 10: Financials 2024 – income statement by region
Financials 2024 – income statement Holding EUR m EMEA Americas Asia Pacific companies Total Gross profit 2024 553 361 289 1,202 2023 530 340 253 1,123 organic growth 2% 0% 2% 1% acquisition growth 3% 7% 14% 7% currency impact (1%) (1%) (2%) (1%) Operating EBITA 2024 241 158 170 (39) 531 2023 242 155
Slide 11: Financials 2024 – income statement (continued)
Financials 2024 – income statement (continued) fx adj. 2024 2023 change change EUR m change Operating EBITA 531 515 16 3% 5% Net finance costs (45) (25) (20) Amortisation of intangible assets (95) (81) (14) Acquisition costs/one-off adjustments - (11) (5) (6) income and expenses Income tax expenses
Slide 12: Financials 2024 – net finance costs
Financials 2024 – net finance costs 2024 2023 change EUR m Interest costs financing structure (60) (41) (19) Interest expenses lease liabilities (5) (3) (2) Amortisation of finance costs (2) (2) - Changes deferred considerations 36 29 7 Interest costs re employee benefits (0) (0) - Currency exchange
Slide 13: Financials 2024 – income tax expenses and income tax %
Financials 2024 – income tax expenses and income tax % 2024 2023 change EUR m Regular income tax expenses (115) (120) 5 Tax credits related to amortisation 11 9 2 Other 3 0 3 Income tax expenses (102) (111) 9 2024 2023 change EUR m Operating EBITA minus acquisition costs/one-off adjustments and fina
Slide 14: Financials 2024 – cash EPS and proposed dividend
Financials 2024 – cash EPS and proposed dividend 2024 2023 change EUR m Result for the year 278 292 (5%) Amortisation of intangible assets 95 81 Tax credits related to amortisation (11) (9) Cash earnings 363 365 (1%) Weighted average number of share (x million) 57.2 56.9 0.3 Cash earnings per share
Slide 15: Financials 2024 – balance sheet
Financials 2024 – balance sheet 31/12/2024 31/12/2023 change EUR m Property, plant and equipment 42 36 6 Right-of-use assets 103 100 3 Intangible assets 2,609 2,260 348 Other financial assets/deferred tax assets 55 50 6 Total working capital 907 764 143 Provisions/employee benefits (47) (46) (1) Def
Slide 16: Financials 2024 – year-end working capital
Financials 2024 – year-end working capital 2024 2023 2022 2021 2020 EUR m 821 732 702 619 469 722 622 581 526 371 -391 -389 -403 -292 -478 -105 -158 -165 -130 -158 2024 2023 2022 2021 2020 Inventories in days of revenue1 55 46 48 54 46 Receivables in days of revenue1 61 58 54 63 58 Payables in days
Slide 17: Financials 2024 – net debt
Financials 2024 – net debt 31/12/2024 31/12/2023 change Maturity profile as of 31/12/2024 EUR m EUR m Loans and borrowings long term 1,397 1,250 147 1200 Loans and borrowings short term 300 - 300 1000 Short term financial liabilities 110 430 (320) 800 Cash and cash equivalents (525) (394) (131) Net
Slide 18: Financials 2024 – free cash flow
Financials 2024 – free cash flow 2024 2023 change EUR m Operating EBITA 531 515 16 Depreciation 41 33 8 Operating EBITDA 572 548 25 Lease payments (32) (26) (6) Share based payments 4 5 (1) Adjusted Operating EBITDA 544 526 17 Capex (11) (10) (1) ∆ Working capital1 (83) 38 (121) Free cash flow 450 5
Slide 19: Outlook
Highlights Financials Outlook Q&A Annex 2024 FY2024
Slide 20: Outlook
Outlook IMCD operates in different, often fragmented market segments in multiple geographic regions, connecting many customers and suppliers across a very diverse product range. In general, results are impacted by macroeconomic conditions and developments in specific industries. Results can be influ
Slide 21: Q&A
Highlights Financials Outlook Q&A Annex 2024 FY2024
Slide 22: Annex
Highlights Financials Outlook Q&A Annex 2024 FY2024
Slide 23: Profile
Profile IMCD is a market leader in the sales, marketing and distribution of speciality chemicals and ingredients Highlights: ● Formulatory and solutions provider ● Comprehensive and complementary product portfolio ● Multi-territory distribution management in EMEA, Asia-Pacific and Americas ● Headqua
Slide 24: 8 business groups, focusing on strategic market segments
8 business groups, focusing on strategic market segments Pharmaceuticals Coatings & Construction Food & Nutrition Advanced Materials Excipients; APIs; nutraceuticals; Coatings; decorative paints; Dairy; savoury; bakery; beverage; Compounders; converters; synthesis; agrochemicals; adhesives & sealant
Slide 25: High scores on external ESG ratings
High scores on external ESG ratings Demonstrating our continuous focus on best practices Score B (2024) Gold (2024) Score B (2023) Gold (2023) On a scale of A to D- ESG Risk Rating 12.6, low risk (2024) C+ (Prime) rating 13.7 (2023) C rating (2023) On a scale of A+ to D- 25
Slide 26: Disclaimer
Disclaimer This presentation may contain forward looking statements. These statements are based on current expectations, estimates and projections of IMCD’s management and information currently available to the company. IMCD cautions that such statements contain elements of risk and uncertainties th